Regeneron Pharmaceuticals REGN Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's operating cash flow?
- Regeneron Pharmaceuticals (REGN) reported operating cash flow of $1.08B in Q1 2026.
- How has Regeneron Pharmaceuticals's operating cash flow changed year-over-year?
- Regeneron Pharmaceuticals's operating cash flow increased by 3.2% year-over-year, from $1.05B to $1.08B.
- What is the long-term trend for Regeneron Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's operating cash flow has grown at a -8.4% compound annual growth rate (CAGR), from $7.08B to $4.98B.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.